Net sales of $81.6 million GAAP net loss of $0.03 per share; Adjusted (Non-GAAP) net income of $0.08 per share Adjusted EBITDA of $12.7 million , or $0.37 per share; 54% growth over Q3 FY12 Operating cash flow of $10 million versus $6.8 million in prior year ALBANY, N.Y.

ALBANY, N.Y. , March 27, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced that it will report its fiscal 2013 third quarter financial

ALBANY, N.Y. , March 8, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, is scheduled to present at the Barclays Global Healthcare Conference on Tuesday,

Conference Call Scheduled for March 8, 2013 at 8:30 a.m. ET

ALBANY, N.Y. , Feb. 13, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, is scheduled to present at the RBC Capital Markets Global Healthcare Conference

ALBANY, N.Y. , Feb. 1, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today said it has completed the previously announced acquisition of certain

ALBANY, N.Y. , Jan. 23, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it has exercised the option to purchase certain assets of

ALBANY, N.Y. , Jan. 15, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced that it will host an investor and analyst meeting on Wednesday,

Pro forma net sales growth of 3% to $87 million Adjusted (Non-GAAP) Net Income of $0.10 per share; GAAP Net Income of $0.06 per share Adjusted EBITDA of $13.8 million ; or $0.39 per share, a 26% YOY increase Operating cash flow of $11.1 million ALBANY, N.Y. , Jan.

ALBANY, N.Y. , Jan. 3, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology is scheduled to present at the J.P.

ALBANY, N.Y. , Dec. 19, 2012 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced that it will report its fiscal 2013 second quarter financial

ALBANY, N.Y. , Dec. 17, 2012 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the appointment of George W.

ALBANY, N.Y. , Nov. 19, 2012 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced Executive Vice President and Chief Financial Officer Joseph

ALBANY, N.Y. , Nov. 19, 2012 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology is scheduled to present at the 24th Annual Piper Jaffray Healthcare Conference at

ALBANY, N.Y. , Oct. 16, 2012 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced that it has completed the acquisition of Vortex Medical Inc.

Net sales of $83.4 million GAAP net loss of $0.02 per share; Adjusted (Non-GAAP) net income of $0.10 per share, a YOY 25% increase Integration of Navilyst Medical yielding significant cost savings Vortex Medical acquisition to strengthen peripheral vascular portfolio ALBANY, N.Y. , Oct.

Strengthens Peripheral Vascular Product Portfolio and Advances Venous Disease Strategy

Contract With HealthTrust Covers Chronic & Acute Dialysis Catheters

ALBANY, N.Y. , Oct. 4, 2012 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced a recent court action in its legal case against biolitec Inc.

ALBANY, N.Y. , Sept. 27, 2012 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the appointment of Louis J.